UGT1A1 and Hyperbilirubinemia: Bykova et al. found that patients who had the homozygous genotype of the (TA)7/(TA)7 (*28/*28) for UGT1A1 were more likely to have grade 3 hyperbilirubinemia (mostly of the indirect bilirubin fraction) when treated with nilotinib [51].